Background: Coronary artery spasm (CAS) is one of the important etiological factors for patients (pts) with chest pain but no coronary artery stenosis. Generally smoking and other factors were known the clinical risk factors for CAS. However, clinical aspects related to age on CAS have been seldom investigated and reported. We investigated whether there is any impact of old age on CAS and as compared with younger age by intracoronary acetylcholine (Ach) provocation test. Methods: A total 2954 consecutive pts without significant coronary artery lesion who underwent Ach provocation test by injecting incremental doses of 20, 50, 100 ug into the left coronary artery between March 2004 and April 2009 were enrolled. Significant CAS was defined as focal or diffuse severe transient luminal narrowing (>70%) with/without chest pain or ST-T change on ECG. the Ach provocation test results and its associated parameters were compared between the younger pt group (<50 years old, n=1044 pts, mean age; 41.13 ± 7.4 years) and older pt group (≥50 years old, n=1910 pts, mean age; 62.06 ± 7.44). Results: Baseline clinical characteristics were similar between the two groups except that more male (58.3% vs. 42.0%, p<0.001) and smoker (38.9% vs. 24.3%, p<0.001) in younger patients group whereas more diabetes mellitus (16.3% vs. 6.0%, p<0.001), dyslipidemia (21.3% vs. 13.1%, p<0.001) and hypertension (54.2% vs. 32.6%, p<0.001) in older patients group. The rate of positive Ach provocation test was higher in the older pts group. Further, older pts group showed higher incidence of diffuse and multi-vessel spasm (Table) .
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(Abstract nos 437 -467) Background: The opening of the mitochondrial permeability transition pore (mPTP) is a critical determinant of ischaemia-reperfusion injury, and the inhibition of its opening confers powerful cardioprotection. Whether this cardioprotective effect is present in the setting of hypertrophic cardiomyopathy (HCM) is investigated in this study. Methods: Human cardiomyocytes were isolated from left ventricular septal tissue, harvested from patients undergoing surgical myectomy for obstructive HCM. The cells were loaded with the fluorescent dye TMRM which localises to the mitochondria and generates oxidative stress on confocal imaging. This results in mPTP opening indicated by collapse of the mitochondrial membrane potential. Time taken to induce loss of mitochondrial membrane potential was used as a measure of mPTP opening sensitivity. Cells were randomised as follows: (1)DMSO 0.01% vehicle control (N=8/group) (2)Cells pre-treated with ciclosporin-A (CsA)(0.2μM) for 15 mins (N=7/group) (3)Cells pre-treated with atorvastatin(25μM)(N=7/group) Results: In the control group mPTP opening was induced after 188.7±22.7 seconds of oxidative stress, providing evidence for a functional mPTP in HCM. Furthermore, pretreatment with the known mPTP inhibitor, CsA, and atorvastatin, delayed the onset of mPTP opening by 51±10% (P<0.001) and 35±7% (P<0.05), respectively. Methods: Right atrial appendages were harvested from consenting adult patients undergoing elective cardiac surgery. From these, individual atrial trabeculae were explanted. Trabeculae were then suspended in an organ bath and subjected to 90 minutes hypoxia followed by 120 minutes reoxygenation in order to simulate ischaemia-reperfusion injury (IRI). At the end of the protocol, recovery of contractile function was determined and compared to baseline. Trabeculae were randomised into the following groups: Control (N=14); Hypoxic preconditioning (positive control)
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, a specific inducible NOS inhibitor (N=5); Inhibitors and vehicle agents alone had no effect on recovery (N=18 performed. Under fluoroscopy, nab-rapamycin (Abraxis Bioscience) (5 or 500 μg) or vehicle was delivered to the adventitia using a micro-infusion catheter (Mercator MedSystems). After 28 days,the arteries were harvested. The primary outcome was histomorphometric evidence of luminal stenosis and remodeling. Vessel injury was scored on a validated ordinal scale. Results: There was 100% procedural success in 16 injury sites treated with adventitial injections. Nab-rapamycin treated vessels had significantly larger lumen (p=0.01, ANOVA) and total vessel areas (p=0.005) indicating less negative remodeling. Percent luminal stenosis and maximal intimal width decreased in a dose-dependent fashion. Control vessels had significantly more fibrosis (p<0.001). Mean values for measured and calculated metrics for 16 injured femoral segments treated with adventitial injection of vehicle or nab-rapamycin *p-values based on ANOVA Conclusion: These data suggest that adventitial delivery of rapamycin decreases luminal stenosis by inhibiting IH and preventing negative remodeling. The decreased fibrosis in treated vessels suggests a mechanism by which rapamycin may affect vessel remodeling following injury. Background: Mesenchymal precursor cells (MPC) are cells that exerted therapeutic actions in pre-clinical models of acute myocardial infarction (AMI). They are immune privileged and can be given in an allogeneic setting. The aim of the current large animal study was to assess the effect of intracoronary delivery of allogeneic MPC directly following an AMI. Methods: The 30 sheep that survived the anterior AMI were blindly randomized to receive IC infusion of either saline (n=10) or three incremental doses of allogeneic MPC (n=20). Cardiac function was assessed using echocardiography. After 8 weeks, sheep were sacrificed and the hearts excised for morphometric and histological analysis. Results: In the control group, global LVEF deteriorated to 36.6±2.0%, whereas it was enhanced in treated sheep to 45.4±1.4% (p= 0.009). Also regional function improved, as fractional area change (FAC) in the apex increased by 39% in MPC-treated animals compared to controls (p=0.027), and FAC in the mid-ventricle increased by 30% (p=0.007). Local systolic wall thickening in the affected antero-septal wall improved from 9.6±5.5% in controls to 39.1±1.8% in treated animals (p< 0.001) and in the anterior wall from 13.8± 3.6% to 34.7±1.9% (p<0.001). Morphometric analysis revealed that MPC treatment resulted in a 40% reduction in infarct size from 18.2±1.7% in control animals to only 10.9±0.6% in treated sheep (p<0.001). Also, infarct (p<0.001) and border zone (p=0.011) thickness were enhanced in the treatment group. Histological analysis showed an increase in blood vessel density of >50% in the infarct (p<0.001), remote (p=0.007) and border (p<0.001) areas evoked by MPC therapy. In addition, cardiomyocyte size was smaller in border (p<0.001) and remote (p=0.002) areas, accompanied by reduced collagen contents, suggestive of decreased remodeling. Conclusion: Intracoronary delivery of allogeneic MPC directly after the AMI resulted in preserved global and regional cardiac function, evoked by reduced infarct size, increased perfusion and reduced remodeling. Background: Renal sympathetic nerve hyperactivity contributes to resistant hypertension. Recent innovation with catheter-based ablation of renal nerves has shown efficacy in reducing blood pressure without procedural mortality. We hypothesize that pharmacologic sympathectomy with guanethidine monosulfate (GNT) delivered to renal peri-adventitial tissue would produce sustained renal artery denervation. Methods: A micro-infusion catheter (Bullfrog®, Mercator MedSystems, Inc.) was introduced via femoral artery into renal arteries of (N=15) swine. GNT (50 mg/6 ml, N=12) or vehicle (6 ml, N=3) was infused to the peri-adventitia of each renal artery under fluoroscopic guidance. Subjects were divided between a pharmacokinetic (PK) experiment with 3 treated subjects each sacrificed at 1, 7 or 28 days, and a histology experiment with 3 treated and 3 control subjects sacrificed at 28 days. The primary efficacy endpoint for both experiments was kidney NE tissue content. Secondary outcomes were plasma and tissue GNT levels, histological evidence of renal artery denervation and renal artery injury.
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Results:
The 24 treated and 6 control renal arteries had 100% procedural success in the delivery of GNT or vehicle. Histology showed optimal healing in injected renal arteries: complete endothelialization, no thrombus formation, no or minimal nonstenosing neointima and no or minimal medial fibrosis, with no difference between treated and control arteries (p=NS). There was a time-dependent decrease in renal NE content, dropping 20±16% (p=NS) by 7 days and 58±10% (p<0.024) at 28 days, each compared to vehicle controls at 28 days. Denervation was evident from NE drops and from histology, with reduced fiber density and endo-and peri-neurial fibrosis in GNTinjected animals, but no neuronal changes evident in vehicle controls. PK analysis revealed GNT retention of 54 ng/g around the renal arteries at 28 days. By contrast, GNT plasma concentrations were below adrenergic blocking levels at 24 hours postinjection. Conclusion: GNT, delivered to the renal peri-adventitia resulted in a time-dependent reduction in kidney NE content and specific immune-mediated destruction of renal artery perivascular nerve tissue. Peri-adventitial drug delivery appears to be a safe and efficient modality to maximize tissue concentration while minimizing plasma spillover.
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